Tuesday 21 March 2023 - in person and virtual event
This study day will provide an update in the field of lung cancer whilst looking at the patient holistically. We will look at new treatment options, clinical trials and the impact that treatment (or no treatment) has on patients.
Suitable for nurses, allied health professionals (AHPs) and all clinicians with an interest in lung cancer.
| Time | Session |
|---|---|
| 9.15 | Welcome and introduction |
| 9.30 | Chairperson's welcome Professor Janelle Yorke, Chief nurse, The Christie NHS Foundation Trust |
| 9.45 | Small cell pathway Emma Halkyard, Lung cancer nurse clinician, The Christie NHS Foundation Trust |
| 10.00 | 1st-line treatments in extensive stage small cell lung cancer Professor Raffaele Califano, Consultant in medical oncology, The Christie NHS Foundation Trust |
| 10.30 | Research in small cell lung cancers Dr Laura Molliner, Clinical fellow in medical oncology, The Christie NHS Foundation Trust |
| 10.50 | Management of paraneoplastic syndromes in small cell lung cancer Dr Paul Taylor, Consultant in medical oncology, The Christie NHS Foundation Trust |
| 11.20 | Break |
| 11.30 | Overview of radiotherapy treatments Prof Corinne Faivre-Finn, Consultant in clinical oncology, The Christie NHS Foundation Trust |
| 12.00 | Importance of molecular testing in non-small cell lung cancer (NSCLC) Mr Mathew Carter, Scientific officer, The Christie NHS Foundation Trust |
| 12.30 | Overview of treatment advances in NSCLC Dr Yvonne Summers, Consultant in medical oncology, The Christie NHS Foundation Trust |
| 13.00 | Lunch |
| 13.30 | Steroid induced psychosis Dr Asanga Fernando, Consultant liaison psychiatrist, St Georges NHS Foundation Trust |
| 14.00 | One Stop Lung Clinic Sr Karen Peplow, Lung cancer clinical nurse specialist, Manchester University NHS Foundation Trust |
| 14.30 | Overview of the Senior adult oncology service Naomi Farrington, Senior adult oncology service implementation lead, The Christie NHS Foundation Trust |
| 15.00 | Break |
| 15.15 | Ruth Strauss Foundation Ms Deepa Doshi, Head of Mission Services, The Ruth Strauss Foundation |
| 15.45 | Patient stories |
| 16.15 | Close |
Takeda Oncology aspire to cure cancer, with inspiration from patients and innovation from everywhere.
Delivering on the unique needs of patients, who have limited or ineffective treatment options, is at the centre of everything they do. They live this philosophy through their Patient-Trust-Reputation-Business decision-making framework.
Takeda Oncology strive to provide transformative therapies, developed from ground-breaking science, to dramatically improve patients’ lives.
Grounded in more than 240 years of Japanese heritage, they are built on Takeda’s legacy foundation. They benefit from the international resources of a top biopharmaceutical leader, whilst also being structured for agility. As a patient-driven research and development organisation, Takeda Oncology are collaborative, nimble and fast to meet the needs of the cancer community.
You can learn more about the company on the Takeda onocology website.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
It's an exciting time as Bayer aims to develop products that improve people’s quality of life. They concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways, with the potential to impact not just the treatment of common cancers, but rarer cancers as well.
Irwin Mitchell LLP has over 30 years’ experience in successfully recovering compensation for clients whose lives have been affected by mesothelioma and other asbestos-related illnesses. Their specialist solicitors are based nationwide and have helped and supported several thousand clients after exposure to asbestos through their work, domestic or environmental circumstances.
They have the largest team of asbestos solicitors in the UK, and have won several landmark victories that have led to significant changes in the law including the first ever successful case of environmental exposure in 1995, and the first settlement including hospice costs as well as compensation.
Sign up to our education events mailing list to be kept up to date with this and future events
© 2023 The Christie NHS Foundation Trust
The Christie Charity